Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA)

被引:24
作者
Abdalrhman, Ihab [1 ]
Gurt, Irina [1 ]
Katz, Ehud [1 ]
机构
[1] Hebrew Univ Jerusalem, Dept Virol, Hadassah Med Sch, IL-91120 Jerusalem, Israel
关键词
vaccinia; Lister/Elstree; MVA;
D O I
10.1016/j.vaccine.2006.02.012
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The Lister (Elstree) strain of vaccinia virus, used in Israel for vaccination against smallpox, was studied in tissue cultures and in a mouse model. The virus failed to reach the brain of the mice when inoculated intranasally at a dose of 500,000 plaque forming units, but was lethal for 50% of them, when injected intracranially. Lower doses of virus injected intracranially caused some weight loss initially, but later the mice completely recovered. Modified vaccinia virus Ankara (MVA), when infected intranasally, did not spread beyond the lungs to other organs of the mice. Even when the mice were inoculated with MVA intracranially, they were not affected. Significant protection against a lethal dose of an orthopoxvirus was obtained in mice following immunization with the Lister strain, while larger doses and repeated vaccination procedure, were required with MVA. The Lister virus stock applied in Israel, was found to be heterogeneous in its plaque morphology. Two variants isolated from it, showed significant attenuation for mice, when inoculated intranasally and intracranially, as compared to a third variant and to the unpurified stock of the virus. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4152 / 4160
页数:9
相关论文
共 24 条
[1]   Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses [J].
Belyakov, IM ;
Earl, P ;
Dzutsev, A ;
Kuznetsov, VA ;
Lemon, M ;
Wyatt, LS ;
Snyder, JT ;
Ahlers, JD ;
Franchini, G ;
Moss, B ;
Berzofsky, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (16) :9458-9463
[2]   Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model [J].
Brandt, TA ;
Jacobs, BL .
JOURNAL OF VIROLOGY, 2001, 75 (02) :850-856
[3]   Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: Propagation and generation of recombinant viruses in a nonhuman mammalian cell line [J].
Carroll, MW ;
Moss, B .
VIROLOGY, 1997, 238 (02) :198-211
[4]   Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines [J].
Drexler, I ;
Staib, C ;
Kastenmüller, W ;
Stevanovic, S ;
Schmidt, B ;
Lemonnier, FA ;
Rammensee, HG ;
Busch, DH ;
Bernhard, H ;
Erfle, V ;
Sutter, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (01) :217-222
[5]   THE PERSISTENCE OF NEUTRALIZING ANTIBODIES AFTER REVACCINATION AGAINST SMALLPOX [J].
ELAD, B ;
ROTH, Y ;
WINDER, A ;
TOCHNER, Z ;
LUBLINTENNENBAUM, T ;
KATZ, E ;
SCHWARTZ, T .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (03) :446-448
[6]   Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells [J].
Guerra, S ;
López-Fernández, LA ;
Conde, R ;
Pascual-Montano, A ;
Harshman, K ;
Esteban, M .
JOURNAL OF VIROLOGY, 2004, 78 (11) :5820-5834
[7]  
HENDERSON DA, 1999, VACCINES, P74
[8]  
HOCHSTEI.V, 1972, Z IMMUNITATSFORSCH, V144, P140
[9]   Mouse neurotoxicity test for vaccinia-based smallpox vaccines [J].
Li, ZQ ;
Rubin, SA ;
Taffs, RE ;
Merchlinsky, M ;
Ye, ZP ;
Carbone, KM .
VACCINE, 2004, 22 (11-12) :1486-1493
[10]  
LUBLIN-TENNENBAUM T, 1990, Viral Immunology, V3, P19, DOI 10.1089/vim.1990.3.19